Experimental therapies that target the immune system have expanded greatly in recent years due to the success of immune checkpoint inhibitory antibodies. Preclinical development of these novel immuno-oncology drugs requires the availability of well-characterized syngeneic tumor mouse models to evaluate therapeutic mode of action, efficacy, and safety.
Proper analysis of the data generated from these models can give valuable insight into the mode of action and model responses to these novel drugs. Join us as we discuss a recent study with two syngeneic mouse models and how bioinformatics analysis was able to determine their response to treatment.
Patrick Fadden, PhD
Dominic Pearce, PhD
Senior Bioinformatics Developer
Have a scheduling conflict? Sign up even if you can't make it; we'll share the recording after.
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.